Pharvaris (PHVS) Earnings Date & Reports

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

PHVS is expected to report earnings to fall 9.04% to -77 cents per share on July 25

Q2'25

Est.

$-0.77

Q1'25

Missed

by $0.12

Q4'24

Beat

by $0.08

Q3'24

Missed

by $0.18

Q2'24

Est.

$-0.55

The last earnings report on May 13 showed earnings per share of -85 cents, missing the estimate of -72 cents. With 81.02K shares outstanding, the current market capitalization sits at 866.99M.

View a ticker or compare two or three

Compare

PHVS